Detalhe da pesquisa
1.
Rationale and Design of the SOTA-P-CARDIA Trial (ATRU-V): Sotagliflozin in HFpEF Patients Without Diabetes.
Cardiovasc Drugs Ther
; 2023 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37318685
2.
Prolyl Hydroxylase Inhibitors: a New Opportunity in Renal and Myocardial Protection.
Cardiovasc Drugs Ther
; 36(6): 1187-1196, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34533692
3.
Is the Endothelium the Missing Link in the Pathophysiology and Treatment of COVID-19 Complications?
Cardiovasc Drugs Ther
; 36(3): 547-560, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34097193
4.
Effects of electret coating technology on coronary stent thrombogenicity.
Platelets
; 33(2): 312-319, 2022 Feb 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-33856288
5.
Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the "Cardiac Benefits" of Empagliflozin Independent of its Hypoglycemic Activity?
Cardiovasc Drugs Ther
; 33(1): 87-95, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30675708
6.
Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?
Cardiovasc Drugs Ther
; 32(2): 213-222, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29679303
7.
Pathophysiology of acute coronary syndrome.
Curr Atheroscler Rep
; 16(4): 401, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24504549
8.
Antithrombotic and prohemorrhagic actions of different concentrations of apixaban in patients exposed to single and dual antiplatelet regimens.
Sci Rep
; 13(1): 22969, 2023 12 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38151494
9.
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial.
Eur Heart J
; 32(7): 838-46, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21252171
10.
SGLT2i in heart failure: can their benefits be expanded across the entire spectrum of ejection fraction?
Rev Esp Cardiol (Engl Ed)
; 75(10): 833-841, 2022 Oct.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-35817327
11.
Empagliflozin improves quality of life in nondiabetic HFrEF patients. Sub-analysis of the EMPATROPISM trial.
Diabetes Metab Syndr
; 16(2): 102417, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35121204
12.
Not only how much, but also how to, when measuring epicardial adipose tissue.
Magn Reson Imaging
; 86: 149-151, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34813891
13.
Experimental models for the investigation of high-density lipoprotein-mediated cholesterol efflux.
Curr Atheroscler Rep
; 13(3): 266-76, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21484293
14.
Leuko-platelet index predicts thrombotic events in patients with acute coronary syndrome.
Int J Cardiol
; 328: 29-34, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33301835
15.
Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF: From the EMPA-TROPISM Study.
JACC Heart Fail
; 9(8): 578-589, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34325888
16.
Thrombi of different pathologies: implications for diagnosis and treatment.
Curr Treat Options Cardiovasc Med
; 12(3): 274-91, 2010 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-20842548
17.
Are the antidiabetic SGLT2 inhibitors a cardiovascular treatment? / ¿Son los inhibidores del receptor SGLT2 fármacos antidiabéticos o cardiovasculares?
Clin Investig Arterioscler
; 2020 Oct 21.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-34756346
18.
Internalization of microparticles by platelets is partially mediated by toll-like receptor 4 and enhances platelet thrombogenicity.
Atherosclerosis
; 294: 17-24, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31945614
19.
Genesis and dynamics of atherosclerotic lesions: implications for early detection.
Cerebrovasc Dis
; 27 Suppl 1: 38-47, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19342832
20.
Dual SGLT1 and SGLT2 inhibition: more than the sum of its parts.
Rev Esp Cardiol (Engl Ed)
; 2024 Mar 22.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-38521442